Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature

Figure 2 Imaging data and changes in the carbohydrate antigen 19-9 level during treatment of a patient with newly diagnosed advanced gastric cancer with multiple metastases. A: The patient was diagnosed with gastric cancer. After receiving surgery, KN026 and KN046 for 2 cycles, nivolumab combined with trastuzumab and SOX for 5 cycles, and RC48 plus apatinib sequential maintenance therapy, the patient survived for 31.6 months after the diagnosis of postoperative metastases to the time of this manuscript submission; B: After the patient received third-line treatment with RC48 plus apatinib, his carbohydrate antigen 19-9 level decreased significantly and remained within the normal range during subsequent treatments.